| Dr Thaddeus R Weghorst, MD | |
|
510 Smaltz Way, Auburn, IN 46706-0612 | |
| (260) 927-0035 | |
| (260) 927-0036 |
| Full Name | Dr Thaddeus R Weghorst |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 510 Smaltz Way, Auburn, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912083155 | NPI | - | NPPES |
| 200427390 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 01057752A (Indiana) | Primary |
| Entity Name | Auburn Obgyn Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316082746 PECOS PAC ID: 0042258071 Enrollment ID: O20050420001030 |
News Archive
The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.
Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.
Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
› Verified 9 days ago
| Entity Name | Lutheran Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164662805 PECOS PAC ID: 4981751617 Enrollment ID: O20090414000705 |
News Archive
The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.
Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.
Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
› Verified 9 days ago
| Entity Name | Kosciusko Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932349594 PECOS PAC ID: 5496809956 Enrollment ID: O20090818000398 |
News Archive
The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.
Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.
Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thaddeus R Weghorst, MD 6920 Pointe Inverness Way Ste 200, Fort Wayne, IN 46804-7934 Ph: (260) 927-0035 | Dr Thaddeus R Weghorst, MD 510 Smaltz Way, Auburn, IN 46706-0612 Ph: (260) 927-0035 |
News Archive
The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.
Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.
Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
› Verified 9 days ago
Larson F Langschwager, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1316 E 7th St, Suite 3, Auburn, IN 46706 Phone: 260-333-7704 Fax: 260-333-7705 | |
Joshua Ryan Leichty, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1316 E 7th St Ste 3, Auburn, IN 46706 Phone: 260-333-7704 Fax: 260-333-7705 | |
Kenneth R Chaffee, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1316 E. 7th Street, Suite 3, Auburn, IN 46706 Phone: 260-333-7704 Fax: 260-333-7705 |